CKD Bio Past Earnings Performance
Past criteria checks 0/6
CKD Bio's earnings have been declining at an average annual rate of -75.6%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 5.3% per year.
Key information
-75.6%
Earnings growth rate
-75.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 5.3% |
| Return on equity | -17.6% |
| Net Margin | -14.5% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor Composition
Feb 28
Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?
Feb 01
CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of Debt
Jan 11What CKD Bio Corp.'s (KRX:063160) ROE Can Tell Us
Dec 21Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential
Nov 30Revenue & Expenses BreakdownBeta
How CKD Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 159,935 | -23,130 | 15,057 | 16,277 |
| 30 Jun 23 | 155,183 | -20,233 | 15,377 | 15,272 |
| 31 Mar 23 | 152,876 | -18,403 | 15,251 | 15,341 |
| 31 Dec 22 | 156,042 | -16,703 | 15,513 | 15,432 |
| 30 Sep 22 | 154,395 | -10,462 | 13,971 | 13,939 |
| 30 Jun 22 | 154,759 | -11,222 | 13,750 | 12,777 |
| 31 Mar 22 | 155,569 | -5,821 | 13,246 | 11,940 |
| 31 Dec 21 | 142,238 | -6,577 | 12,585 | 11,516 |
| 30 Sep 21 | 135,760 | -6,730 | 12,105 | 10,878 |
| 30 Jun 21 | 130,483 | -1,111 | 11,355 | 10,667 |
| 31 Mar 21 | 127,741 | 1,771 | 11,109 | 10,114 |
| 31 Dec 20 | 124,600 | 6,207 | 10,538 | 9,118 |
| 30 Sep 20 | 135,773 | 10,664 | 9,873 | 9,900 |
| 30 Jun 20 | 138,042 | 12,633 | 9,852 | 10,455 |
| 31 Mar 20 | 136,265 | 12,446 | 9,718 | 10,584 |
| 31 Dec 19 | 137,184 | 12,265 | 10,057 | 10,704 |
| 30 Sep 19 | 129,529 | 10,563 | 9,913 | 9,919 |
| 30 Jun 19 | 127,134 | 9,605 | 9,347 | 9,074 |
| 31 Dec 18 | 124,510 | 7,956 | 8,530 | 7,881 |
| 30 Sep 13 | 107,444 | 2,379 | 13,651 | 0 |
| 30 Jun 13 | 113,754 | 4,314 | 14,218 | 0 |
Quality Earnings: A063160 is currently unprofitable.
Growing Profit Margin: A063160 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A063160 is unprofitable, and losses have increased over the past 5 years at a rate of 75.6% per year.
Accelerating Growth: Unable to compare A063160's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A063160 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (34.6%).
Return on Equity
High ROE: A063160 has a negative Return on Equity (-17.58%), as it is currently unprofitable.